科研之友
微信
新浪微博
Facebook
分享链接
摘要
Hemangiomas are the most common tumors of infancy affecting 10% of the population. Most cases require no treatment. but treatment is needed because of life threatening locations, local complication). or cosmetic risks. Systemic corticosteroids were the mainstay treatment for complicated infantile hemangiomas, with interferon or vincristine as the second- or third-line treatment. Laser,: cryotherapy, local steroid therapy and surgery are also used. The adverse effects of these various types of treatment are potentially very severe, with partial and questionable response. Propranolol, a nonselective beta-blocker has recently been introduced as a novel modality for. the treatment of hemangiomas with rapid therapeutic effects. Propranolol has a well-documented safety and side effect profile and has been established in therapy of infant cardiovascular diseases decades. The mechanism of action of propranolol includes vasoconstriction, down-regulation of angiogenetic factors such as vascular endothelial growth factor and basic fibroblast growth factor; and an up-regulation of apoptosis of capillary endothelial cells. Propranolol appears to be an effective treatment for infantile hemangiomas and should now be used as a first-line treatment when intervention is required.
- 出版日期2012-11
